This bill inserts two new provisions into the Mandatory Blood Testing Act, 2006 to address what happens when the person whose blood is the subject of an application dies. One clause requires that applications already under way continue after the respondent’s death, subject to regulatory modifications.
The other allows new applications to be filed in respect of someone who is already deceased, with the statute delegating procedural rules to regulations.
The changes are narrowly targeted but consequential: they create a legal pathway for post‑mortem blood testing tied to the existing application framework while giving the Minister broad rule‑making authority to set modified procedures, Board processes, and Superior Court options. Compliance officers, public health officials, coroners, and laboratories will need to follow the regulations that the Minister will later draft to see how these powers operate in practice.
At a Glance
What It Does
Adds section 2.1 to allow an existing blood‑testing application to proceed after the respondent dies, and section 2.2 to permit new applications in respect of deceased persons; both routes rely on regulations to set the altered procedures. It also amends cross‑references in sections 7 and 8 and expands the regulation‑making list in section 11(1).
Who It Affects
Medical officers of health, the Ontario Social Benefits Tribunal (the Board referenced in the Act), public health laboratories, coroners and hospital pathology services, and applicants (victims, investigators, or next‑of‑kin) seeking testing of deceased individuals. The Ministry will gain responsibility for detailed operational rules.
Why It Matters
The bill fills a procedural gap that previously left post‑mortem testing unclear under the Act, but it does so by delegating most practical design to regulations — meaning the real impact depends on forthcoming regulatory content and operational guidance for labs and tribunals.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates two pathways for blood testing when the person whose blood is sought is dead. First, if someone applies while the respondent is alive and the respondent dies before the application is resolved, the application does not automatically terminate; instead it continues under the Act but may be adapted by regulations.
That means the statutory process for medical officers, the Board, and courts can be preserved but altered to reflect the respondent’s death.
Second, the bill permits applications to be brought about a person who is already deceased. In that case the statute removes the default procedures in sections 3 to 6 and requires the application to be handled “in accordance with the regulations.” In short, post‑mortem applications will run mainly on regulatory rules rather than the Act’s living‑person process.To support those two changes, the bill tightens cross‑references in sections 7 and 8 so that penalties and enforcement language refer to the Act as a whole, not just particular sections.
It also expands the Act’s regulation‑making clause (new 11(1)(m) and (n)) to allow the Minister to specify how applications that involve deceased persons should be handled, including steps for medical officers, Board procedures for referrals and hearings, Superior Court powers, and any ancillary matters related to evidence, confidentiality, or testing logistics.The bill does not itself set timelines, evidentiary standards, or laboratory procedures; it relies on the Minister to write regulations that will define those operational details. That means the surface change is small — two added sections and some drafting clean‑up — but the substantive rules that will affect daily practice are yet to be written and will determine how widely and quickly post‑mortem testing is used.
The Five Things You Need to Know
Section 2.1 requires an application made while a respondent is alive to continue after the respondent’s death, subject to regulatory modifications to sections 3–6 and other prescribed rules.
Section 2.2 permits new applications in respect of a person already deceased and expressly removes the default application process in sections 3–6 for those cases, directing that the matter be handled by regulation instead.
The bill gives the Minister broad regulation‑making authority (new section 11(1)(m) and (n)) to specify modifications, steps for medical officers, Board hearing and decision rules, Superior Court procedures, and to govern items tied to existing clauses (f)–(k).
Substantive enforcement and penalty cross‑references in subsections 7(1), 7(2) and section 8 are amended to read “under this Act,” aligning enforcement language with the expanded regulatory pathway.
The Act’s commencement is by order of the Lieutenant Governor in Council, and the bill sets the short title as the Mandatory Blood Testing Amendment Act, 2025 (the bill text, not the external metadata, uses the 2025 short title).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Continuation of applications after respondent’s death
This provision makes an in‑flight application resilient to the respondent’s death: instead of lapsing, the application proceeds under sections 3–6 but may be adjusted by regulations. Practically, that leaves the substantive statutory route intact — medical officer investigations, Board referrals, and possible court involvement — while authorizing regulatory tweaks where death affects procedures (for example, how to obtain a sample or substitute evidence). It is a targeted intervention that preserves legal continuity but anticipates operational differences post‑mortem.
New applications in respect of deceased persons handled by regulation
This clause allows applicants to initiate a blood‑testing request concerning someone already deceased, but it strips out the default sections 3–6 for those cases and substitutes a regulatory regime. The practical consequence is that the Act signals legislative permission but punts the detailed design — evidence rules, who may apply, time limits, and whether the Board or courts adjudicate — to subordinate instruments.
Widened enforcement cross‑references
Amendments to subsection 7(1) and 7(2) replace narrow references to section 3 or Board orders with the broader phrase “under this Act.” That’s drafting housekeeping with a purpose: it makes penalties and enforcement attachments applicable to actions taken under the new regulatory tracks as well as the traditional statutory pathway, avoiding a loophole where post‑mortem proceedings might escape the Act’s enforcement mechanisms.
Aligned references in section 8
Section 8’s amendment mirrors the change made in section 2: enforcement and offences now point to “this Act” rather than individual sections. This prevents a mismatch between where the Act provides powers and where it prescribes penalties, ensuring that regulatory operations will be subject to the same compliance consequences as section‑based orders.
Expanded regulation‑making authority (new s.11(1)(m) and (n))
The bill inserts two new regulatory heads of power. Clause (m) focuses on circumstances following a respondent’s death and authorizes modifications to sections 3–6 plus other rules to keep an application moving. Clause (n) is more granular: it empowers the Minister to prescribe required steps for medical officers, rules for the Board’s handling of referrals (including hearings and decisions), parameters for Superior Court applications and orders, and to regulate matters tied to other clauses (f)–(k). In practice this clause will determine the operational architecture — who does what, when, and on what proof — so the regulations will contain the work‑horse provisions practitioners will actually use.
Commencement and short title
The Act begins on a day chosen by the Lieutenant Governor in Council, giving the government flexibility to delay start until regulations and operational guidance are ready. The bill’s final line sets the short title as the Mandatory Blood Testing Amendment Act, 2025; that is a technical naming clause and does not affect substance, but it is worth noting because it conflicts with the external label of the bill in the metadata.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Applicants seeking post‑mortem testing (victims, next‑of‑kin, investigators): The bill creates an explicit legal route to request blood testing after death, which may allow determination of communicable disease status or other medical facts when a respondent cannot be tested while alive.
- Medical officers of health and public health units: They gain statutory clarity that applications can continue or be initiated where the subject is deceased, enabling public health follow‑up and surveillance consistent with the Act once regulations set procedures.
- Public health and forensic laboratories: A predictable statutory basis for post‑mortem testing can channel more work to qualified labs and clarify sample handling expectations once regulations define procedures.
- Coroners and forensic pathologists: The statutory pathway may complement coroner investigations by creating an administrative route to testing, potentially reducing duplicative court involvement if regulations coordinate with coroner processes.
- Legal representatives and advocacy organizations for survivors: The bill gives counsel a clear statutory mechanism to seek testing in post‑mortem scenarios that previously sat in a grey zone, which can support civil claims or public‑health records requests.
Who Bears the Cost
- Public health units and medical officers of health: They will face new procedural obligations to process post‑mortem applications and to follow regulatory steps, potentially increasing administrative workload and requiring coordination with coroners and labs.
- Public health laboratories and hospital pathology services: Labs must absorb additional testing volume and establish chain‑of‑custody, storage and validation procedures for post‑mortem samples, possibly requiring new capacity or funding.
- The Ministry of Health: The Minister must draft detailed regulations and provide operational guidance; if regulations require new services or funding, the Ministry or health system will need to allocate resources.
- Estates and next‑of‑kin of deceased respondents: Families may confront post‑mortem testing orders or investigations initiated by applicants, raising emotional, privacy and potential legal costs to respond or contest testing.
- The Social Benefits Tribunal / Board and Superior Court: The Board will need to adopt hearing rules for referrals concerning deceased persons and the Superior Court may see new types of applications and orders, increasing tribunal and court caseloads and administrative complexity.
Key Issues
The Core Tension
The central dilemma is between enabling public‑health and legal access to post‑mortem blood testing (which can protect others, support investigations, and resolve claims) and protecting the bodily integrity, privacy and procedural rights of deceased individuals and their families; the bill resolves that dilemma not by statute but by delegating to regulations, transferring the hard choice to the executive and operational actors.
The bill deliberately leaves granular choices to regulation, which speeds legislative passage but centralizes consequential decisions in the executive branch. Key operational details — who may apply in a post‑mortem case, how labs establish provenance for samples, timelines for applications, admissibility standards, and confidentiality protections — are all left undefined until regulations appear.
That delegation creates implementation risk: inconsistent or delayed regulations could leave practitioners with uncertain duties or conflicting obligations across public health, coroners’ offices and hospitals.
There is also a tension between the objective of obtaining medically useful information and protecting the interests of deceased persons and their families. Deceased individuals cannot assert consent, and their estates may have limited procedural standing; the bill provides no statutory guidance on notice to estates, avenues for challenge, or remedies for wrongful testing.
Moreover, the interplay between this Act, coroner law and existing health‑information rules (and any applicable privacy protocols) is not resolved within the text, which raises questions about sequencing (whose authority to test prevails), evidentiary primacy, and record management.
Operationally, laboratories will need validated post‑mortem sampling protocols and clear chain‑of‑custody standards; otherwise, test results may be clinically or legally unreliable. Finally, because the bill amends enforcement cross‑references broadly, actors involved in post‑mortem procedures should expect enforcement and penalty exposure equivalent to living‑person proceedings — a meaningful detail if regulations omit safeguards or timelines.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.